肝癌疼痛与血清HIF-1及VEGF表达的相关性研究  

Correlation of liver cancer pain to the expressions of serum HIF-1 and VEGF

作　　者：朱少功[1] 王维伟[2] 汤高枫[2] 彭江涛 张德志[1] Zhu Shaogong;Wang Weiwei;Tang Gaofeng;Peng Jiangtao;Zhang Dezhi(Department of General Surgery,Zhengzhou People’s Hospital,Zhengzhou 450000,China;Department of Hepatobiliary and Pancreatic Surgery,Henan Provincial People’s Hospital,Zhengzhou 450000,China)

机构地区：[1]郑州人民医院普外科,450000 [2]河南省人民医院肝胆胰外科,郑州450000

出　　处：《中国实用医刊》2020年第15期12-16,共5页Chinese Journal of Practical Medicine

基　　金：河南省科技攻关计划项目(2018020402)。

摘　　要：目的:探讨肝癌疼痛与血清缺氧诱导因子-1(HIF-1)及血管内皮生长因子(VEGF)表达水平的关系。方法:抽取郑州人民医院与河南省人民医院2016年12月至2019年1月收治的肝癌疼痛患者130例设为研究组(轻度疼痛41例、中度疼痛53例、重度疼痛36例),另选取同期收治的未发生疼痛的肝癌患者130例设为对照组。所有患者入院后均于第2天晨起抽取空腹静脉血2 ml,以酶联免疫吸附法测定血清HIF-1及VEGF水平。研究组肝癌疼痛患者采用"三阶梯止痛"法治疗。统计研究组与对照组、研究组不同疼痛程度患者血清HIF-1及VEGF水平。分析研究组治疗前后血清HIF-1及VEGF水平,并统计分析血清HIF-1及VEGF水平与肝癌疼痛程度的相关性。结果:研究组血清HIF-1[(163.82±31.18)pg/ml]及VEGF[(272.53±33.37)pg/ml]水平高于对照组[(62.71±20.79)、(101.67±22.31)pg/ml],P<0.05。研究组重度疼痛患者血清HIF-1[(189.93±30.67)pg/ml]及VEGF[(298.78±32.15)pg/ml]水平高于中度疼痛患者[(168.69±27.79)、(274.61±28.26)pg/ml],P<0.05;中度疼痛患者血清HIF-1及VEGF水平高于轻度疼痛患者[(151.71±23.07)、(249.42±24.29)pg/ml],P<0.05。治疗后,研究组血清HIF-1及VEGF水平较治疗前降低(P<0.05)。Pearson检验显示,血清HIF-1及VEGF水平与肝癌疼痛程度呈正相关关系(r=0.812、0.781,P均<0.05)。结论:肝癌疼痛患者血清HIF-1及VEGF表达水平异常增高,在不同疼痛程度患者间其血清含量存在显著差异,两者间存在明显正相关关系,且患者经对应止痛治疗后血清HIF-1及VEGF表达水平均降低。Objective To investigate the relationship of liver cancer pain with the expression levels of hypoxia-inducible factor-1(HIF-1)and vascular endothelial growth factor(VEGF).Methods A total of 130 patients with liver cancer pain treated in Zhengzhou People’s Hospital and Henan Provincial People’s Hospital from December 2016 to January 2019 were selected as the study group(41 cases of mild pain,53 cases of moderate pain,36 cases of severe pain).Another 130 liver cancer patients without pain in the same period were selected as control group.On the morning of the 2nd day after admission,2 ml fasting venous blood was collected from every patient.The levels of serum HIF-1 and VEGF were measured by enzyme-linked immunosorbent assay.And patients in the study group were treated with the"three steps analgesic"method.Serum levels of HIF-1 and VEGF of the control group and patients with different pain levels of the study group were recorded.The serum preoperative amd postoperative levels of HIF-1 and VEGF of the study group were analyzed.And the correlation of levels of HIF-1 and VEGF with liver cancer pain was analyzed statistically.Results The levels of serum HIF-1 and VEGF were(163.82±31.18)pg/ml and(272.53±33.37)pg/ml respectively in the study group,significantly higher than the(62.71±20.79)pg/ml and(101.67±22.31)pg/ml in the control group(P<0.05).In the study group,levels of serum HIF-1 and VEGF of patients with severe pain were(189.93±30.67)pg/ml and(298.78±32.15)pg/ml,respectively,which were significantly higher than the(168.69±27.79)pg/ml and(274.61±28.26)pg/ml of patients with moderate pain(P<0.05);and levels of serum HIF-1 and VEGF of patients with mild pain were(151.71±23.07)pg/ml and(249.42±24.29)pg/ml,respectively,which were lower than those of patients with moderate pain(P<0.05).The levels of serum HIF-1 and VEGF of the study group decreased after treatment(P<0.05).Pearson test showed that there was a significant positive correlation of levels of serum HIF-1 and VEGF with liver cancer pain severity(

关 键 词：肝癌 疼痛 疼痛程度 临床分期 缺氧诱导因子-1 血管内皮生长因子 

分 类 号：R735.7[医药卫生—肿瘤]